Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
Annexon, Inc. - common stock (ANNX)
Company Research
Source: GlobeNewswire
ANX005-Treated Patients Demonstrated Faster and More Complete Recovery from Week 1 through Week 26 on Primary and Multiple Pre-Specified Endpoints Two and a Half Times More ANX005-Treated Patients Returned to a Normal / Pre-Disease State of Health Over Placebo on GBS-DS by Week 26, Increasing Over Time ANX005 Beneficial Impact Larger in Patients with North American and European Baseline Characteristics Across Key Measures of Disability and Muscle Strength Single Infusion of ANX005 was Generally Well-Tolerated with Safety Profile Similar to Placebo Data Reinforce Potential of ANX005 to be First Targeted Immunotherapy Treatment for GBS BRISBANE, Calif., June 25, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), today announced positive results from the completed pivotal Phase 3 trial of C1q-targeted immunotherapy, ANX005, in Guillain-Barré Syndrome (GBS) at the 2024 Peripheral Nerve Society (PNS) Annual Meeting in Montréal, Canada. Leading global experts in the GBS field
Show less
Read more
Impact Snapshot
Event Time:
ANNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANNX alerts
High impacting Annexon, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
ANNX
News
- Are Medical Stocks Lagging Annexon (ANNX) This Year? [Yahoo! Finance]Yahoo! Finance
- Treating Geographic Atrophy Remains a Tough Call for Ophthalmologists as They Voice Hesitancy to Prescribe Complement Inhibitors [Yahoo! Finance]Yahoo! Finance
- Huntington's Disease Pipeline Research 2024: Insights About 20+ Companies and 25+ Pipeline Drugs - Therapeutic Assessment by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]Yahoo! Finance
- Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barré Syndrome At 2024 PNS Annual Meeting [Yahoo! Finance]Yahoo! Finance
ANNX
Earnings
- 5/13/24 - Beat
ANNX
Sec Filings
- 6/25/24 - Form 8-K
- 6/12/24 - Form 8-K
- 6/7/24 - Form 4
- ANNX's page on the SEC website